Saltar al contenido

Noticias y sala de prensa

Atrás

SOLTI en SABCS 2017

SOLTI en SABCS 2017

SOLTI in SABCS 2017

05 dic 2017

A continuación detallamos la presencia de SOLTI en el San Antonio Breast Cancer Symposium para que puedan ver las presentaciones de estudios promovidos o con participación de nuestro grupo que tendrán lugar durante el congreso.

 

6 de diciembre de 2017

[GS1-04] Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial
Authors: Sotiriou C, Roth  F, Maetens M, Fumagalli D, Brown DN, Salgado R, Bradbury I, Pusztai L, Harbeck N, Ignatiadis M, Sarp S, de la Pena L, de Azambuja E, Huober J, Nuciforo P, Baselga J, Piccart M, Loi S, Venet D        

  • Room: Hall 3         
  • Date/Time: Wednesday, December 6, 2017 - 10:15 am         
  • Session Info: Oral Session: General Session 1 (9:30 AM-11:15 AM)         

[GS2-07] MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer  
Authors: Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S, Ruiz Cabrero I, Perell  A, Kendall A, Brown J, Kristeleit H, Conibear J, Saura C, Grenier J, M hr K, Schenker M, Sohn JH, Lee KS, Sarker S-J, Coetzee C, Mousa K, Cortes Castan J        

  • Room: Hall 3         
  • Date/Time: Wednesday, December 6, 2017 - 4:45 pm         
  • Session Info: Oral Session: General Session 2 (3:15 PM-5:00 PM)

 

7 de diciembre de 2017

[PD5-04] Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer
Authors: de Azambuja E, Saura C, Nuciforo P, Frantal S, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Pena L, Dubsky P, Lombard JM, Vuylsteke P, Castaneda Altamirano C, Sanchez C, Ballestrero A, Colleoni M, Santos Borges G, Ciruelos E, Bardia A, Fornier M, Boer K, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Baselga J, Gnant M    

  • Room: Stars at Night Ballroom 1 & 2     
  • Date/Time: Thursday, December 7, 2017 - 5:00 pm     
  • Session Info: Poster Discussion: Endocrine Therapy (5:00 PM-7:00 PM)     

[P2-05-04] Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial  
Authors: Venet D, Roth  F, Dupont F, Maetens M, Fumagalli D, Salgado R, Bradbury I, Pusztai L, Harbeck N, Izquierdo M, de la Pena L, Ignatiadis M, de Azambuja E, Huober J, Nuciforo P, Baselga J, Piccart M, Loi S, Sotiriou C        

  • Room: Hall 1         
  • Date/Time: Thursday, December 7, 2017 - 7:00 am         
  • Session Info: Poster Session 2: Tumor cell and molecular biology: Genomics (7:00 AM-9:00 AM)         

[P2-09-14] A predictive model of pathological response following dual HER2 blockade-only based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer  
Authors: Nuciforo P, Holgado E, Llombart A, Fasani R, Par  L, Pascual T, Oliveira M, Mart nez N, Bermejo B, Vidal M, Pernas S, L pez R, Mu oz M, Garau I, Manso L, Alarc n J, Mart nez E, Villagrasa P, Cort s J, Prat A        

  • Room: Hall 1         
  • Date/Time: Thursday, December 7, 2017 - 7:00 am         
  • Session Info: Poster Session 2: Prognostic and Predictive Factors: Predictive Biomarkers for targeted therapies (7:00 AM-9:00 AM)         

[P2-09-07] Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer  
Authors: Rimm DL, Carvajal-Hausdorf D, Harbeck N, Fumagalli D, Rodrik-Outmezguine V, delaPena L, deAzambuja E, Huober J, Baselga J, Piccart M, Holmes E, Pusztai L        

  • Room: Hall 1         
  • Date/Time: Thursday, December 7, 2017 - 7:00 am         
  • Session Info: Poster Session 2: Prognostic and Predictive Factors: Predictive Biomarkers for targeted therapies (7:00 AM-9:00 AM)         

[P2-09-04] Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer  
Authors: Gavila J, Oliveira M, Pascual T, P rez J, Canes J, Gonz lez X, Par  L, Calvo I, Ciruelos E, Mu oz M, Virizuela JA, Ruiz I, Andr s R, Perell  A, Mart nez J, Morales S, Mar n M, Mart nez D, Quero JC, Llombart-Cussac A, Prat A        

  • Room: Hall 1         
  • Date/Time: Thursday, December 7, 2017 - 7:00 am         
  • Session Info: Poster Session 2: Prognostic and Predictive Factors: Predictive Biomarkers for targeted therapies (7:00 AM-9:00 AM)         

[P2-09-03] Identifying clinically relevant subgroups of women with HER2-positive breast cancer: An analysis of Neo-ALTTO using the 41-gene TRAR score  
Authors: Di Cosimo S, Triulzi T, De Cecco L, Pizzamiglio S, de Azambuja E, Fumagalli D, Pusztai L, Harbeck N, Izquierdo M, de la Pena L, Huober J, Baselga J, Piccart M, Verderio P, Tagliabue E   

  • Room: Hall 1         
  • Date/Time: Thursday, December 7, 2017 - 7:00 am         
  • Session Info: Poster Session 2: Prognostic and Predictive Factors: Predictive Biomarkers for targeted therapies (7:00 AM-9:00 AM)         

[P2-09-12] Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer  
Authors: Prat A, De Angelis C, Pascual T, Gutierrez C, Wang T, Par  L, Rexer B, Cortes J, Forero A, Llombart A, Wolff AC, Krop I, Galv n P, Pavlick AC, Villagrasa P, Hilsenbeck SG, Schiff R, Osborne CK, Rimawi MF

  • Room: Hall 1
  • Date/Time: Thursday, December 7, 2017 - 7:00 am
  • Session Info: Poster Session 2: Prognostic and Predictive Factors: Predictive Biomarkers for targeted therapies (7:00 AM-9:00 AM)      

 

8 de diciembre de 2017

[P5-18-02] Nab-Paclitaxel-based therapy in the first line treatment of metastatic breast cancer (IBCSG 42-12/BIG 2-12 SNAP): Impact of different schedules on quality of life  
Authors: Ribi K, Sun Z, Jerusalem G, Hasler-Strub U, Colleoni M, von Moos R, Cort s J, Vidal M, Hennessy B, Walshe J, Amillano Parraga K, Morales Muriilo S, Pagani O, Barbeaux A, Bortsnar S, Maibach R, Regan MM, Gennari A, Bernhard J

  • Room: Hall 1         
  • Date/Time: Friday, December 8, 2017 - 5:00 pm
  • Session Info: Poster Session 5: Psychosocial, QOL, and Educational Aspects: Psychosocial Aspects (5:00 PM-7:00 PM)         

[OT3-05-07] PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer  
Authors: Metzger-Filho O, Mandrekar S, Loibl S, Ciruelos E, Gianni L, Lim E, Miller K, Huang C, Koehler M, Francis P, Valagussa P, Goel S, Prat A, Goetz M, Loi S, Krop I, Carey L, Lanzillotti J, Winer E, Tripathy D, DeMichele A

  • Room: Hall 1
  • Date/Time: Friday, December 8, 2017 - 5:00 pm
  • Session Info: Ongoing Clinical Trials: Targeted- CDH 4/6 (5:00 PM-7:00 PM)     

[P5-20-19] PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial  
Authors: Ciruelos E, Villagrasa P, Par  L, Oliveira M, de la Pe a L, Pernas S, Cort s J, Soberino J, Adamo B, Vazquez S, Mart nez N, Perell  A, Bermejo B, Mart nez E, Garau I, Mel  M, Morales S, Galvan P, Pascual T, Nuciforo P, Gonzalez X, Prat A      

  • Room: Hall 1
  • Date/Time: Friday, December 8, 2017 - 5:00 pm
  • Session Info: Poster Session 5: Treatment: Her2-targeted therapy (5:00 PM-7:00 PM)

 

9 de diciembre de 2017

[P6-15-06] SOLTI-0702 CAPRICE: Final results of a phase II study of pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as neoadjuvant chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: 5-year overall survival disease free survival and late cardiac safety
Authors: Gil-Gil M, Bellet M, Morales S, Barnadas A, Manso L, Morilla Ruiz I, Azaro A, Ciruelos Gil E, Garcia Mart nez E, Mar nez N, Mel  M, Soler T, Villagrasa P, Pernas S

  • Room: Hall 1
  • Date/Time: Saturday, December 9, 2017 - 7:00 am
  • Session Info: Poster Session 6: Treatment: Neoadjuvant chemotherapy (7:00 AM-9:00 AM)    

 

(Hora de San Antonio, Texas, EEUU)


Contactos

Área de Comunicación SOLTI
X

En Grupo Solti utilizamos cookies, propias y de terceros, analíticas, publicitarias y de elaboración de perfiles, basadas en hábitos de navegación del usuario, para mejorar la calidad del servicio, medir la audiencia y ofrecerle publicidad que pueda ser de su interés. Puede obtener más información en nuestra Política de Cookies.

Entendemos que acepta el uso de cookies en caso de que siga navegando.

Puede gestionar las cookies y aceptarlas o rechazarlas en el Panel de Configuración.